1. Home
  2. SKYE vs SNTI Comparison

SKYE vs SNTI Comparison

Compare SKYE & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$0.14

Market Cap

5.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
SNTI
Founded
2012
2016
Country
United States
United States
Employees
N/A
39
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.7M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
SKYE
SNTI
Price
$1.18
$0.14
Analyst Decision
Buy
Buy
Analyst Count
4
2
Target Price
★ $68.00
$13.50
AVG Volume (30 Days)
98.4K
★ 1.2M
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.31
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$127.27
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.26
$0.14
52 Week High
$11.68
$57.60

Technical Indicators

Market Signals
Indicator
SKYE
SNTI
Relative Strength Index (RSI) 44.62 14.66
Support Level $0.26 N/A
Resistance Level $1.66 $0.24
Average True Range (ATR) 0.20 0.03
MACD -0.00 0.23
Stochastic Oscillator 62.05 4.89

Price Performance

Historical Comparison
SKYE
SNTI

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: